Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial
- PMID: 14550427
- DOI: 10.1016/s0090-4295(03)00583-1
Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial
Abstract
Objectives: To perform a Canadian multicenter randomized placebo-controlled trial to evaluate the safety and efficacy of 6 weeks of levofloxacin therapy compared with placebo in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Uncontrolled studies have supported the use of antibiotics in CP/CPPS.
Methods: Men with a National Institutes of Health (NIH) diagnosis of CP/CPPS (specifically, no infection localized to the prostate) were randomized to levofloxacin (500 mg/day) or placebo for 6 weeks in 11 Canadian centers. Patients were assessed at baseline and at 3, 6, and 12 weeks with the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and global patient assessments (subjective global assessment and patient assessment questionnaire).
Results: Eighty men (average age 56.0 years, range 36 to 78; duration of symptoms 6.5 years, range 0.6 to 32) were randomized to receive levofloxacin (n = 45) or placebo (n = 35). All were evaluated in an intent-to-treat analysis. Both groups experienced progressive improvement in symptoms as measured by the NIH-CPSI. However, the difference in response was not statistically or clinically significant at end of treatment (6 weeks) or at the end of the follow-up visits (12 weeks). No patients withdrew because of adverse events. One patient withdrew before the 6-week assessment. Adverse events (all mild) were reported in 20% of the levofloxacin group and 17% of the placebo group.
Conclusions: This pilot placebo-controlled study showed that 6 weeks of levofloxacin therapy in men diagnosed with CP/CPPS resulted in symptom improvement that was not significantly different from that with placebo at end of treatment or follow-up. The clinical ramifications of these findings need to be addressed.
Similar articles
-
Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.Urology. 2003 Sep;62(3):425-9. doi: 10.1016/s0090-4295(03)00466-7. Urology. 2003. PMID: 12946740 Clinical Trial.
-
Pentosan polysulfate therapy for chronic nonbacterial prostatitis (chronic pelvic pain syndrome category IIIA): a prospective multicenter clinical trial.Urology. 2000 Sep 1;56(3):413-7. doi: 10.1016/s0090-4295(00)00685-3. Urology. 2000. PMID: 10962305 Clinical Trial.
-
Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial.Ann Intern Med. 2004 Oct 19;141(8):581-9. doi: 10.7326/0003-4819-141-8-200410190-00005. Ann Intern Med. 2004. PMID: 15492337 Clinical Trial.
-
α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome.BJU Int. 2012 Oct;110(7):1014-22. doi: 10.1111/j.1464-410X.2012.11088.x. Epub 2012 Apr 3. BJU Int. 2012. PMID: 22471591 Review.
-
Pregabalin for chronic prostatitis.Cochrane Database Syst Rev. 2012 Aug 15;(8):CD009063. doi: 10.1002/14651858.CD009063.pub2. Cochrane Database Syst Rev. 2012. PMID: 22895982 Review.
Cited by
-
Transcatheter Arterial Embolization for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Retrospective Study of 44 Patients.Cardiovasc Intervent Radiol. 2024 Aug 27. doi: 10.1007/s00270-024-03842-6. Online ahead of print. Cardiovasc Intervent Radiol. 2024. PMID: 39191997
-
Biological evaluation of levofloxacin and its thionated derivatives: antioxidant activity, aldehyde dehydrogenase enzyme inhibition, and cytotoxicity on A549 cell line.Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr 13. doi: 10.1007/s00210-024-03075-x. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38613572
-
Expression Profiling of L5-S2 Spinal Cord Dorsal Horn in a Rat Model of Chronic Pelvic Pain Syndrome Uncovers Potential Mechanism of Electroacupuncture Mediated Inflammation and Pain Responses.J Pain Res. 2022 Jul 26;15:2067-2084. doi: 10.2147/JPR.S364972. eCollection 2022. J Pain Res. 2022. PMID: 35923840 Free PMC article.
-
The efficacy and safety of low-intensity extracorporeal shock wave treatment combined with or without medications in Chronic prostatitis/chronic pelvic pain syndrome: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2023 Sep;26(3):483-494. doi: 10.1038/s41391-022-00571-0. Epub 2022 Jul 7. Prostate Cancer Prostatic Dis. 2023. PMID: 35798855 Review.
-
Oral pharmacological treatments for chronic prostatitis/chronic pelvic pain syndrome: A systematic review and network meta-analysis of randomised controlled trials.EClinicalMedicine. 2022 May 20;48:101457. doi: 10.1016/j.eclinm.2022.101457. eCollection 2022 Jun. EClinicalMedicine. 2022. PMID: 35706494 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous